Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...
US pharma giant Pfizer has announced positive results from the Phase III TALAPRO-2 study of Talzenna (talazoparib), an oral ...
Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...
GlobalData on MSN11h
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoCResults from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Prostate cancer cells usually require male androgen hormones, such as testosterone, to grow. Androgen deprivation therapy ...
Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...
Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...
Evan Y. Yu, MD, discusses other ongoing investigations exploring combinations based on radium-223 (Ra-223), highlighting ...
Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower ...
In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback